Extended Data Fig. 6: Neutralization, binding and fine specificity of vaccine- and infection-elicited plasma Abs against emerging Omicron variants in dialysis patients, kidney transplant recipients and healthy individuals.

a,b, Neutralization of SARS-CoV-2 pseudotyped VSV carrying Wu-G614, BA.1, BA.5, BA.2.75.2, BQ.1.1, XBB.1 and XBB.1.5 (upper panels) by plasma Abs and binding to matched RBDs by plasma IgGs from dialysis patients (DP) (a) or kidney transplant recipients (KTR) (b) after receiving 4 (Wu₄vacc) doses. Samples are compared to those from healthcare workers (HCW) collected 2–4 weeks (a) or 2–4 months (b) after receiving 3 or 4 doses of monovalent Wu vaccine. Shown are ID₅₀ values from n = 2 technical replicates. Bars and values on top represent geometric mean ID₅₀ titers (GMT). Fold-loss of neutralization against Omicron variants as compared to Wu-G614 is shown above each corresponding bar. Horizontal dashed lines indicate the limit of detection in the neutralization assay (ID₅₀ = 40) and the cut-off in the ELISA assay based on binding to uncoated plates (ED₅₀ = 50). Cohort demographics are summarized in Supplementary Table 6. Statistically significant differences of mean neutralization and binding titers within and between cohorts are shown in Supplementary Table 8. c, Competition ELISA (blockade of binding) between individual S site-specific monoclonal Abs and plasma from vaccinated individuals (cohorts v-viii). S2V29 binds to the RBM. Each plot shows the magnitude of inhibition of binding to immobilized Wu-G614, BQ.1.1 and XBB.1 S in the presence of each monoclonal Ab, expressed as reciprocal plasma dilution blocking 80% of the maximum binding response (BD₈₀). Points represent the BD₈₀ measured for each individual plasma donor as determined from n = 1 experiment and bars represent geometric mean BD₈₀ titers.